Livtencity

maribavir

Approval

ApplicationNDA 215596
Approval dateNov 23, 2021
Approval year2021
SponsorTakeda Pharms USA

FDA-approved use

To treat post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMV

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Livtencity: